0000899243-19-002654.txt : 20190205 0000899243-19-002654.hdr.sgml : 20190205 20190205172723 ACCESSION NUMBER: 0000899243-19-002654 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190201 FILED AS OF DATE: 20190205 DATE AS OF CHANGE: 20190205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fairey William CENTRAL INDEX KEY: 0001727275 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37609 FILM NUMBER: 19568999 MAIL ADDRESS: STREET 1: C/O CHEMOCENTRYX, INC. STREET 2: 850 MAUDE AVE. CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MyoKardia Inc CENTRAL INDEX KEY: 0001552451 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455500552 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-741-0900 MAIL ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-01 0 0001552451 MyoKardia Inc MYOK 0001727275 Fairey William C/O MYOKARDIA, INC. 333 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Stock Option (Right to Buy) 40.99 2019-02-01 4 A 0 69500 0.00 A 2029-01-31 Common Stock 69500 69500 D Restricted Stock Units 2019-02-01 4 A 0 32500 0.00 A Common Stock 32500 32500 D The option shall vest and become exercisable as to 25% of the option on February 1, 2020 and in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The units shall vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Executive Vice President, Chief Commercial Officer /s/ Cynthia Ladd as Attorney-in-Fact 2019-02-05